Keheala Announces Investment by Check Point Software Technologies Co-Founder, Marius Nacht

Marius Nacht, Co-Founder of Checkpoint Software Technologies and aMoon Fund.

Marius Nacht, Co-Founder of Checkpoint Software Technologies and aMoon Fund.

Keheala has announced an investment from Check Point Software Technologies (Nasdaq: CHKP) Co-Founder, Marius Nacht. This investment will help Keheala scale its operations, pursue new products and enter new markets. The seed investment is Keheala’s first equity deal bringing total outside capital to approximately one million dollars. Previously, Keheala has received two non-dilutive grants from the U.S. Agency for International Development (USAID).

Nacht first approached Keheala following its presentation at the 8200 Social Program’s Demo Day, expressing excitement for Keheala’s potential to “reduce global drug resistance while improving healthcare delivery in regions with significant need.” Marius went on, “Doing good will lead to a good business.”

Jon Rathauser, Keheala’s CEO & Founder, commented, “A strategic mixture of dilutive and non-dilutive funding has always been the goal; one source suggests the importance of our work for accomplishing development goals, the other suggests the means for sustaining our impact into the future.” Rathauser continued, "Marius's investment is recognition of Keheala's business potential that will sustain our health-improving intervention."

Marius Nacht is known for co-founding cybersecurity-giant Check Point, which he still serves as Chairman. More recently, Nacht founded aMoon Fund, a “Life Sciences venture fund investing in breakthrough innovations focused on accelerating cures of common killers and revolutionizing the biggest cost-drivers of global healthcare.” 

Keheala delivers behavioral interventions across mobile phones to improve healthcare access and treatment outcomes for infectious and chronic disease patients across the developing world. In a 1200 patient randomized controlled trial, tuberculosis patients using Keheala's intervention demonstrated a two-thirds reduction in the unsuccessful treatment outcomes of death, failed treatment and loss to follow up.

For inquiries, please e-mail